Plymouth Meeting-based Inovio teams up with AIDS Malignancy Consortium for immunotherapy study

Inovio Pharmaceuticals, Inc. has entered into a partnership with the AIDS Malignancy Consortium to evaluate VGX-3100 as a potential therapy for HIV-positive adult men and women. The Plymouth Meeting, Pa., biopharmaceutical company is developing VGX-3100, an immunotherapy designed to boost the ability of person's immune system to fight diseases, as a treatment for human papillomavirus (HPV)-associated precancerous conditions. Under the terms of the partnership, the consor tium will fund a mid-stageā€¦
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news